Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.

Ruff CT, Patel SM, Giugliano RP, Morrow DA, Hug B, Kuder JF, Goodrich EL, Chen SA, Goodman SG, Joung B, Kiss RG, Spinar J, Wojakowski W, Weitz JI, Murphy SA, Wiviott SD, Parkar S, Bloomfield D, Sabatine MS, AZALEA–TIMI 71 Investigators

Open source

DOI: 10.1056/nejmoa2406674
Published: 2025 Jan 23
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2406674,
  title = {Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.},
  author = {Ruff CT and Patel SM and Giugliano RP and Morrow DA and Hug B and Kuder JF and Goodrich EL and Chen SA and Goodman SG and Joung B and Kiss RG and Spinar J and Wojakowski W and Weitz JI and Murphy SA and Wiviott SD and Parkar S and Bloomfield D and Sabatine MS and AZALEA–TIMI 71 Investigators},
  year = {2025},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2406674},
  url = {https://doi.org/10.1056/nejmoa2406674}
}

RIS

TY  - JOUR
TI  - Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
AU  - Ruff CT
AU  - Patel SM
AU  - Giugliano RP
AU  - Morrow DA
AU  - Hug B
AU  - Kuder JF
AU  - Goodrich EL
AU  - Chen SA
AU  - Goodman SG
AU  - Joung B
AU  - Kiss RG
AU  - Spinar J
AU  - Wojakowski W
AU  - Weitz JI
AU  - Murphy SA
AU  - Wiviott SD
AU  - Parkar S
AU  - Bloomfield D
AU  - Sabatine MS
AU  - AZALEA–TIMI 71 Investigators
PY  - 2025
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2406674
UR  - https://doi.org/10.1056/nejmoa2406674
ER  -

APA

CT, R., SM, P., RP, G., DA, M., B, H., JF, K., EL, G., SA, C., SG, G., B, J., RG, K., J, S., W, W., JI, W., SA, M., SD, W., S, P., D, B., MS, S., & Investigators, A. 7. (2025). Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2406674

Source records

pubmed · retrieved 2026-09-26T02:55:47.394Z